Yayınlar & Eserler

Yayın Ağı
Makaleler 11
Tümü (11)
SCI-E, SSCI, AHCI (11)
SCI-E, SSCI, AHCI, ESCI (11)
Scopus (11)
TRDizin (2)

1. Predicting extra-musculoskeletal and peripheral manifestations and their role on biologic treatment in patients with axial spondyloarthritis: TReasure experience

Ediboglu E. D., KALYONCU U., SOLMAZ D., YAŞAR BİLGE N. Ş., Yilmaz S., Bes C., et al.
ARCHIVES OF RHEUMATOLOGY , sa.1, ss.1-14, 2025 (SCI-Expanded, Scopus, TRDizin) identifier identifier

2. Computed tomography imaging-based radiologic evaluation of pulmonary artery thrombosis in a series of patients with Behcet's disease

GERME Ş. A., ÖZSOY Z., Bulat B., DURHAN G., FIRLATAN B., KILIÇ L., et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES , cilt.27, sa.7, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

3. Apical fibrobullous lung disease in spondyloarthritis patients with biologic DMARDs indication

ÖZSOY Z., AYAN G., DURHAN G., KALYONCU U.
Rheumatology (United Kingdom) , cilt.63, sa.4, ss.1147-1152, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

4. Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)

BİLGİN E., Demirci Yıldırım T., Özdemir Ulusoy B., Öğüt T. S., Karabacak M., Sadioğlu Çağdaş Ö., et al.
Internal and Emergency Medicine , 2024 (SCI-Expanded, Scopus) identifier identifier identifier

5. Factors that predict development of chronic kidney disease in patients with rheumatoid arthritis receiving biologic DMARDs and mortality rates

Sandal Uzun G., Taghiyeva A., Çakır İ. Y., Moral K., YARDIMCI G. K., Bölek E. Ç., et al.
International Journal of Rheumatic Diseases , cilt.27, sa.1, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

6. Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry

Duran E., Ozturk Z. O., BİLGİN E., BÜYÜKAŞIK Y., DİZDAR Ö., Yardimci G. K., et al.
Rheumatology and Therapy , cilt.10, sa.4, ss.969-981, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

7. Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?

ÖZSOY Z., ÖZDEMİR A., EKİCİ M., BİLGİN E., KILIÇ L., KİRAZ S., et al.
Rheumatology International , cilt.43, sa.8, ss.1445-1451, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

8. Comparison of demographic, clinic and radiological features of patients with axial spondyloarthritis accompanying familial Mediterranean fever to patients with each condition alone

Kiracı M., BİLGİN E., Duran E., Farisoğulları B., Bölek E., Yardımcı G., et al.
Scandinavian Journal of Rheumatology , cilt.52, sa.5, ss.530-538, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

9. Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results

AYAN G., Farisogullari B., BİLGİN E., BÖLEK E. Ç., KubraYardimci G., DURAN E., et al.
CLINICAL RHEUMATOLOGY , cilt.41, sa.5, ss.1439-1446, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

10. Reactivation of inflammatory monoarthritis during dupilumab treatment used for prurigo nodularis

Bostan E., GÜLSEREN D., ÖZSOY Z., Ergen F. B.
Archives of Rheumatology , cilt.37, sa.1, ss.148-149, 2022 (SCI-Expanded, Scopus, TRDizin) identifier identifier identifier

11. Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloarthritis Patients with and Without Accompanying Familial Mediterranean Fever

Kiraci M., BİLGİN E., Duran E., Farisogullari B., Bolek E. C., YARDIMCI G. K., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.73, ss.771-773, 2021 (SCI-Expanded, Scopus) identifier
Metrikler

Yayın

11

Yayın (WoS)

11

Yayın (Scopus)

11

Atıf (WoS)

1

H-İndeks (WoS)

1

Atıf (Scopus)

6

H-İndeks (Scopus)

1

Atıf (Scholar)

1

H-İndeks (Scholar)

1

Proje

1